ADAR1-circRAB5A-BIP axis linked to radiotherapy resistance in colorectal cancer
The study identifies the ADAR1-circRAB5A-BIP axis as a key regulator of radiotherapy resistance in colorectal cancer by balancing autophagy and apoptosis.
Phase III
colorectal cancer patients
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Strategic implication
Portfolio teams should consider research into targeting the ADAR1-circRAB5A-BIP axis to enhance radiotherapy efficacy in colorectal cancer treatments.
Why it matters
The identification of the ADAR1-circRAB5A-BIP axis as a regulator of radiotherapy resistance in colorectal cancer presents a significant opportunity for innovation in treatment strategies.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor ongoing research and clinical trials targeting the ADAR1-circRAB5A-BIP pathway and its implications for CRC treatment.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.